These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23114535)
1. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma. Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535 [TBL] [Abstract][Full Text] [Related]
2. Identification of genes correlated with early-stage bladder cancer progression. Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863 [TBL] [Abstract][Full Text] [Related]
3. Bladder Tumor Subtype Commitment Occurs in Carcinoma Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889 [TBL] [Abstract][Full Text] [Related]
4. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033 [TBL] [Abstract][Full Text] [Related]
5. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. Clark PE; Stein JP; Groshen SG; Miranda G; Cai J; Lieskovsky G; Skinner DG J Urol; 2004 Oct; 172(4 Pt 1):1342-7. PubMed ID: 15371837 [TBL] [Abstract][Full Text] [Related]
6. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310 [TBL] [Abstract][Full Text] [Related]
7. [Transitional cell carcinoma of the prostate in cystoprostatectomy specimens]. Liedberg F; Chebil G; Davidsson T; Malmström PU; Sherif A; Månsson W Aktuelle Urol; 2003 Sep; 34(5):333-6. PubMed ID: 14566661 [TBL] [Abstract][Full Text] [Related]
8. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Sun W; Zhang PL; Herrera GA Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230 [TBL] [Abstract][Full Text] [Related]
14. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa. Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077 [TBL] [Abstract][Full Text] [Related]
15. Genetic and molecular markers of urothelial premalignancy and malignancy. Cordon-Cardo C; Cote RJ; Sauter G Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907 [TBL] [Abstract][Full Text] [Related]
16. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486 [TBL] [Abstract][Full Text] [Related]
18. Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread. Park HS; Shin HB; Lee MS; Kim JH; Kim SY; Park J Cancer Res Treat; 2020 Oct; 52(4):1283-1287. PubMed ID: 32192274 [TBL] [Abstract][Full Text] [Related]
19. Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness. Wittschieber D; Stenzinger A; Klauschen F; Stephan C; Jung K; Erbersdobler A; Rabien A Pathobiology; 2011; 78(3):123-31. PubMed ID: 21613799 [TBL] [Abstract][Full Text] [Related]
20. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma. Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]